TN2015000198A1 - Novel pharmaceutical composition - Google Patents

Novel pharmaceutical composition

Info

Publication number: TN2015000198A1
Authority: TN; Tunisia
Prior art keywords: novel pharmaceutical; pharmaceutical composition; dimethyl; trioxo; pyrido
Prior art date: 2012-11-30

Application number

TNP2015000198A

Other languages

English (en)

Inventor

Gossett Campbell

Francisco Henriquez

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-30

Filing date

2015-05-22

Publication date

2016-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-22 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2016-10-03 Publication of TN2015000198A1 publication Critical patent/TN2015000198A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

TNP2015000198A 2012-11-30 2015-05-22 Novel pharmaceutical composition TN2015000198A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261731597P	2012-11-30	2012-11-30
PCT/US2013/071816 WO2014085371A1 (fr)	2012-11-30	2013-11-26	Nouvelle composition pharmaceutique

Publications (1)

Publication Number	Publication Date
TN2015000198A1 true TN2015000198A1 (en)	2016-10-03

Family

ID=50828398

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000198A TN2015000198A1 (en)	2012-11-30	2015-05-22	Novel pharmaceutical composition

Country Status (29)

Country	Link
US (2)	US20150328320A1 (fr)
EP (2)	EP3400933A1 (fr)
JP (1)	JP6232443B2 (fr)
KR (1)	KR102206432B1 (fr)
CN (2)	CN107970214A (fr)
AR (1)	AR093648A1 (fr)
AU (1)	AU2013352369B2 (fr)
BR (1)	BR112015012111A8 (fr)
CA (1)	CA2891346A1 (fr)
CL (1)	CL2015001459A1 (fr)
EA (2)	EA201791411A1 (fr)
ES (1)	ES2686730T3 (fr)
HK (1)	HK1209047A1 (fr)
IL (3)	IL266415B2 (fr)
IN (1)	IN2015DN04094A (fr)
MA (1)	MA38121A1 (fr)
MX (1)	MX2015006867A (fr)
MY (1)	MY170427A (fr)
NZ (1)	NZ628395A (fr)
PE (1)	PE20151024A1 (fr)
PH (1)	PH12015501168A1 (fr)
PL (1)	PL2925299T3 (fr)
PT (1)	PT2925299T (fr)
SG (1)	SG11201503688SA (fr)
TN (1)	TN2015000198A1 (fr)
TW (2)	TW201434468A (fr)
UY (1)	UY35157A (fr)
WO (1)	WO2014085371A1 (fr)
ZA (1)	ZA201503346B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102293907B1 (ko) *	2015-06-30	2021-08-26	한미약품 주식회사	이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) *	2016-04-29	2020-06-11	Alvin Kershman	Method of Coating an Edible Thermoplastic Pet Chew
EP3545957A4 (fr) *	2016-11-25	2020-07-22	Jiangsu Hengrui Medicine Co., Ltd.	Composition pharmaceutique de dérivés de la pyridone et son procédé de préparation
KR102230721B1 (ko) *	2019-02-01	2021-03-22	주식회사 오스코텍	피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
WO2021081554A1 (fr) *	2019-10-22	2021-04-29	Chemistryrx	Méthodes de traitement de l'hyperplasie épidermique congénitale
WO2023219465A1 (fr) *	2022-05-12	2023-11-16	주식회사 지뉴브	Composition pharmaceutique liquide stable

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5559235A (en)	1991-10-29	1996-09-24	Glaxo Wellcome Inc.	Water soluble camptothecin derivatives
US5342947A (en)	1992-10-09	1994-08-30	Glaxo Inc.	Preparation of water soluble camptothecin derivatives
US5681835A (en)	1994-04-25	1997-10-28	Glaxo Wellcome Inc.	Non-steroidal ligands for the estrogen receptor
US5491237A (en)	1994-05-03	1996-02-13	Glaxo Wellcome Inc.	Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) *	1997-11-26	2000-06-20	Pfizer Inc.	Droloxifene pharmaceutical compositions
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
MXPA06014478A (es) *	2004-06-11	2007-03-21	Japan Tobacco Inc	Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
ATE499109T1 (de) *	2004-12-07	2011-03-15	Proteolix Inc	Zusammensetzung zur proteasomhemmung
CN1872055A (zh) *	2005-06-01	2006-12-06	李�杰	适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
PL2583668T3 (pl) *	2005-10-26	2015-05-29	Cydex Pharmaceuticals Inc	Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
NZ579098A (en) *	2007-01-16	2012-07-27	Bipar Sciences Inc	Formulations for cancer treatment
UY30892A1 (es)	2007-02-07	2008-09-02	Smithkline Beckman Corp	Inhibidores de la actividad akt
CN101352419B (zh) *	2007-07-26	2010-08-11	天津药物研究院	一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) *	2007-11-22	2015-01-05	에스케이케미칼주식회사	재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
PL3560498T3 (pl) *	2009-10-16	2022-12-12	Novartis Ag	Kombinacja zawierająca inhibitor mek i inhibitor b-raf
WO2012062743A1 (fr)	2010-11-11	2012-05-18	Bayer Pharma Aktiengesellschaft	2,3-dihydroimidazo[1,2-c]quinolines à substitution arylaminoalcool
TWI505828B (zh)	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	新穎醫藥組成物
US20130023531A1 (en)	2011-01-27	2013-01-24	Boehringer Ingelheim International Gmbh	Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
WO2012118632A1 (fr)	2011-02-28	2012-09-07	Ning Xi	Quinoléines substituées et leurs méthodes d'utilisation
SI2694510T1 (sl) *	2011-04-07	2016-02-29	Bayer Intellectual Property Gmbh	Imidazopiridazini kot inhibitorji AKT kinaze
CN102600132B (zh) *	2012-03-13	2014-05-14	齐鲁制药有限公司	一种含氨磺必利的口服制剂
CN102626394A (zh) *	2012-03-15	2012-08-08	合肥科大生物技术有限公司	一种精氨酸布洛芬颗粒剂及其制备方法

2013
- 2013-11-26 EA EA201791411A patent/EA201791411A1/ru unknown
- 2013-11-26 KR KR1020157016931A patent/KR102206432B1/ko active IP Right Grant
- 2013-11-26 MA MA38121A patent/MA38121A1/fr unknown
- 2013-11-26 IL IL266415A patent/IL266415B2/en unknown
- 2013-11-26 MX MX2015006867A patent/MX2015006867A/es unknown
- 2013-11-26 IL IL300664A patent/IL300664A/en unknown
- 2013-11-26 PL PL13857873T patent/PL2925299T3/pl unknown
- 2013-11-26 NZ NZ628395A patent/NZ628395A/en not_active IP Right Cessation
- 2013-11-26 AU AU2013352369A patent/AU2013352369B2/en active Active
- 2013-11-26 JP JP2015545165A patent/JP6232443B2/ja active Active
- 2013-11-26 EA EA201591047A patent/EA028246B1/ru not_active IP Right Cessation
- 2013-11-26 PT PT13857873T patent/PT2925299T/pt unknown
- 2013-11-26 CN CN201711343653.XA patent/CN107970214A/zh active Pending
- 2013-11-26 US US14/647,606 patent/US20150328320A1/en not_active Abandoned
- 2013-11-26 WO PCT/US2013/071816 patent/WO2014085371A1/fr active Application Filing
- 2013-11-26 CA CA2891346A patent/CA2891346A1/fr not_active Abandoned
- 2013-11-26 ES ES13857873.7T patent/ES2686730T3/es active Active
- 2013-11-26 PE PE2015000701A patent/PE20151024A1/es not_active Application Discontinuation
- 2013-11-26 EP EP18173387.4A patent/EP3400933A1/fr active Pending
- 2013-11-26 BR BR112015012111A patent/BR112015012111A8/pt not_active IP Right Cessation
- 2013-11-26 EP EP13857873.7A patent/EP2925299B1/fr not_active Revoked
- 2013-11-26 CN CN201380062796.7A patent/CN104902876B/zh active Active
- 2013-11-26 SG SG11201503688SA patent/SG11201503688SA/en unknown
- 2013-11-26 MY MYPI2015001232A patent/MY170427A/en unknown
- 2013-11-26 IN IN4094DEN2015 patent/IN2015DN04094A/en unknown
- 2013-11-28 AR ARP130104392A patent/AR093648A1/es unknown
- 2013-11-28 TW TW102143365A patent/TW201434468A/zh unknown
- 2013-11-28 TW TW106137040A patent/TW201831187A/zh unknown
- 2013-11-28 UY UY0001035157A patent/UY35157A/es unknown
2015
- 2015-05-13 ZA ZA2015/03346A patent/ZA201503346B/en unknown
- 2015-05-21 IL IL238971A patent/IL238971B/en active IP Right Grant
- 2015-05-22 TN TNP2015000198A patent/TN2015000198A1/fr unknown
- 2015-05-26 PH PH12015501168A patent/PH12015501168A1/en unknown
- 2015-05-29 CL CL2015001459A patent/CL2015001459A1/es unknown
- 2015-10-07 HK HK15109780.8A patent/HK1209047A1/xx unknown
2017
- 2017-03-07 US US15/451,888 patent/US20170189408A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20170189408A1 (en)	2017-07-06
TW201434468A (zh)	2014-09-16
NZ628395A (en)	2016-10-28
PT2925299T (pt)	2018-10-16
EP3400933A1 (fr)	2018-11-14
KR20150091352A (ko)	2015-08-10
PL2925299T3 (pl)	2018-11-30
MA38121A1 (fr)	2016-10-31
BR112015012111A8 (pt)	2018-01-23
WO2014085371A1 (fr)	2014-06-05
IL238971A0 (en)	2015-07-30
IL266415B2 (en)	2024-03-01
IL266415A (en)	2019-06-30
CN107970214A (zh)	2018-05-01
EA201791411A1 (ru)	2018-03-30
MY170427A (en)	2019-07-31
KR102206432B1 (ko)	2021-01-22
UY35157A (es)	2014-06-30
CN104902876B (zh)	2018-01-19
PE20151024A1 (es)	2015-07-27
HK1209047A1 (en)	2016-03-24
IL300664A (en)	2023-04-01
EA201591047A1 (ru)	2015-11-30
TW201831187A (zh)	2018-09-01
CA2891346A1 (fr)	2014-06-05
CN104902876A (zh)	2015-09-09
EA028246B1 (ru)	2017-10-31
EP2925299B1 (fr)	2018-06-06
US20150328320A1 (en)	2015-11-19
IL238971B (en)	2019-05-30
MX2015006867A (es)	2015-10-05
EP2925299A1 (fr)	2015-10-07
BR112015012111A2 (pt)	2017-07-11
IL266415B1 (en)	2023-11-01
JP6232443B2 (ja)	2017-11-15
ES2686730T3 (es)	2018-10-19
PH12015501168A1 (en)	2015-08-10
SG11201503688SA (en)	2015-06-29
AR093648A1 (es)	2015-06-17
CL2015001459A1 (es)	2015-12-18
AU2013352369B2 (en)	2016-07-28
IN2015DN04094A (fr)	2015-10-09
JP2016501874A (ja)	2016-01-21
ZA201503346B (en)	2016-01-27
EP2925299A4 (fr)	2016-06-29
AU2013352369A1 (en)	2015-05-28

Publication	Publication Date	Title
JO3594B1 (ar)	2020-07-05	تركيبة صيدلانية جديدة
PH12015501168A1 (en)	2015-08-10	Novel pharmaceutical composition
IN2014KN01664A (fr)	2015-10-23
ZA201406149B (en)	2016-06-29	Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
IL230874A (en)	2016-07-31	History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
MX363347B (es)	2019-03-20	Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IL223795A (en)	2015-11-30	History of Tetrahydro-Pyrido-Pyrimidine
EP3515420C0 (fr)	2023-11-08	Compositions pharmaceutiques pour une utilisation dans une thérapie de la blépharite
IL219424A (en)	2015-03-31	Imidazo derivative [b – 1,2] pyridazine, combinations, distant preparations containing them and process for their preparation and use as pde10 inhibitors
MX2013001677A (es)	2013-07-22	Formulaciones estables de linaclotida.
PH12015501302A1 (en)	2016-02-01	Compositions comprising vortioxetine and donepezil
IL233825A (en)	2017-03-30	H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
MX2014008390A (es)	2014-09-22	Formulaciones de romidepsina y sus usos.
MX2018014790A (es)	2019-04-25	Formulacion combinada de tres compuestos antivirales.
IL224683A (en)	2016-03-31	7,6-Dihydro-h3-Oxazolo [4,3-a] pyrazine-8,5-Derivative Processes, Preparation Processes and Pharmaceutical Preparations Containing Them
ZA201500410B (en)	2016-01-27	Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
MX367773B (es)	2019-09-05	Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IL218801A (en)	2015-03-31	Combination containing n - {3 - [3 - cyclopropyl - 5 - (2 - fluoro - 4 - iodo - phenylamino) 6,8 - dimethyl - 2, 4, 7 - trioxo - 3, 4, 6, 7 - tetrahydro - 2 h - Pyrido [4, 3 – d] pyrimidine – 1 – yl] phenyl} acetamide, and n - {(1s) –2– amino-1 - [(3-fluorophenyl) methyl] ethyl} –5-chloro-4 - (4-Chloro-1-Methyl-1H-Pyrazole-5-Yl) -2-Theophenecarboxamide
CO6781490A2 (es)	2013-10-31	Nueva composición farmacéutica
IL266898B (en)	2022-04-01	Solid powder preparations, a process for their preparation, their formulations and their use
ZA201500411B (en)	2016-01-27	Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process